Oncimmune Holdings Plc
("Oncimmune" or the "Company")
Result of Annual General
Meeting
The Annual General Meeting of
Oncimmune Holdings Plc was held at 201 Temple Chambers, 3-7 Temple
Avenue, London, EC4Y 0DT on 27 February 2025 at 10:30
a.m.
Both resolutions put to members were
passed on a poll. Resolution 1 was passed as an ordinary resolution
and resolution 2 was passed as a special resolution.
The number of votes cast for and
against each of the resolutions proposed, and the number of votes
withheld were as follows:
|
Resolution
|
Votes for
|
%
|
Votes against
|
%
|
Votes withheld
|
|
Resolution 1 (Ordinary)
Authority to Allot
|
28,185,261
|
99.50%
|
140,796
|
0.50%
|
49,883
|
|
Resolution 2 (Special)
Disapplication of Statutory
Pre-Emption Rights
|
28,182,361
|
99.49%
|
143,696
|
0.51%
|
49,883
|
The full text of each resolution is
available in the Notice of Annual General Meeting, published on the
Company's website.
For
further information:
contact@oncimmune.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
Geoff Nash, Callum Davidson, Trisyia
Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist
Sales)
Ondraya Swanson (Corporate
Broking)
+44 (0) 20 7220 0500
Zeus
(Joint Broker)
Dominic King
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a precision medicine
company, specialising in analysing immune interactions through the
autoantibody profile. Taking a platform approach to generating
insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations
(CROs) to discover novel biomarkers for the development of more
targeted and effective therapies across many immune-mediated
diseases. Our mission at Oncimmune is to enable precision medicine.
We help our partners to discover novel biomarkers, drug targets and
predict treatment efficacy through the application of our platform.
We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of
experience in the field. Our aim is to make this an essential tool
in drug discovery and development.
Oncimmune is headquartered in the UK,
with its discovery and development facility based in Dortmund,
Germany and a business development team based in the US and
Europe.
For more information,
visit www.oncimmune.com